TNBC is characterized by the absence of estrogen and progesterone receptors, along with human epidermal growth factor receptor 2 (HER2) [2], making it unresponsive to hormone and HER2-targeted therapies that benefit other breast cancer subtypes [3]. The gene discussed is ERBB2; the disease is breast carcinoma.